2025-11-30 - Analysis Report
Here's a comprehensive analysis of TG Therapeutics Inc. (TGTX) based on the provided data:

**0) Overview**

This report analyzes the performance of TG Therapeutics Inc. (TGTX) against the S&P 500 (VOO), examining historical returns, recent stock performance, market indicators, news, analyst opinions, and financial data to provide a comprehensive investment perspective.

**1) Return Rate Comparison**

*   **Ticker:** TGTX (TG Therapeutics Inc.) - A biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 85.33%
*   **VOO (S&P 500) Cumulative Return:** 101.92%
*   **Divergence:** -15.1 (Relative Divergence: 21.1)

**Analysis:** TGTX has underperformed the S&P 500 by approximately 15.1% in cumulative return. The relative divergence of 21.1 suggests that the current divergence is near the lower end of its historical range, indicating potential for improvement or further decline.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD    | Alpha   | Beta  | Cap(B) |
|------------|----------|--------|---------|-------|--------|
| 2015-2017  | -5.0%    | 73.5%  | -33.0%  | -0.0 | 1.3    |
| 2016-2018  | -12.0%   | 73.5%  | -27.0%  | -0.0 | 0.7    |
| 2017-2019  | 74.0%    | 74.1%  | 52.0%   | 0.0 | 1.8    |
| 2018-2020  | 316.0%   | 74.1%  | 293.0%  | 0.1 | 8.3    |
| 2019-2021  | 124.0%   | 74.1%  | 78.0%   | 0.3 | 3.0    |
| 2020-2022  | -71.0%   | 77.8%  | -71.0%  | -0.0 | 1.9    |
| 2021-2023  | -284.0%  | 77.8%  | -285.0% | -1.1 | 2.7    |
| 2022-2024  | 56.0%    | 77.8%  | 36.0%   | -1.0 | 4.8    |
| 2023-2025  | 86.0%    | 80.7%  | 19.0%   | -0.1 | 5.3    |

**Analysis:**

*   **CAGR:** Varies significantly, indicating high volatility.
*   **MDD:** Consistently high, reflecting substantial drawdowns.
*   **Alpha:**  Ranges from highly negative to strongly positive, suggesting inconsistent outperformance.  The most recent periods show positive Alpha, but it's inconsistent.
*   **Beta:** Mostly near zero or negative, suggesting low correlation with the market; the negative beta values in the recent years (2021-2025) suggest the stock moves in the opposite direction of the market.
*   **Cap:** The market capitalization shows growth over time, but with fluctuations.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 33.26
*   **Previous Close:** 33.41
*   **Change:** -0.45
*   **5-day SMA:** 32.726
*   **20-day SMA:** 32.131
*   **60-day SMA:** 33.5474

**Analysis:** The stock price decreased slightly in the last market session. The 5-day and 20-day SMAs are below the 60-day SMA, potentially indicating a short-term upward trend that might be losing momentum.

**3) Market Indicators & Expected Return**

*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 56.47 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.96 (Positive, indicating potential upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (582 shares - Very Safe - MRI:0.90)
*   **Recent Divergence Change:** 1.2 (+), indicating a short-term increase.
*   **Expected Return:** -103.8% (Expected excess return compared to S&P 500 if invested long-term from this point).

**Analysis:** Despite a high MRI suggesting investment, the extremely negative expected return is a significant concern. The RSI and PPO suggest potential short-term positive momentum, but the long-term outlook appears unfavorable according to this metric. A large price change from the previous close could suggest higher volatility.

**4) Recent News & Significant Events**

*   **Earnings Caveat (Nov 3, 2025):** Highlights potential issues impacting earnings, likely contributing to price declines.
*   **Fireside Chat (Nov 28, 2025):** Could be a catalyst for information release and potential price movement.
*   **Financials Look Strong (Oct 31, 2025):** Contradicts some other data points; further investigation needed.
*   **Trending Among Retail Traders (Nov 28, 2025):** Suggests heightened speculative interest.
*   **Positives From Q3'25 Earnings (Nov 17, 2025):**  Highlights positives while also noting increased competition.
*   **Assessing Valuation (Nov 28, 2025):**  Indicates an ongoing evaluation of the stock's worth.

**Analysis:** Recent news is mixed, with positive notes on earnings and financials contrasted by warnings about earnings caveats and competitive pressures. The stock's trending status among retail traders suggests it may be subject to increased volatility.

**4-2) Analyst Opinions**

*   **Consensus:** Not Available
*   **Opinions:** 7 Analysts
*   **Target Price:** 44.29 (Avg), 60.00 (High), 13.00 (Low)
*   **Recent Rating Changes:** None

**Analysis:** The analyst target price range is wide (13.00 to 60.00), indicating considerable uncertainty. The average target price suggests potential upside from the current price, but the lack of recent rating changes provides limited insight.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-11-05 | 2.69  | 0.16 B$     |
| 2025-08-08 | 0.19  | 0.14 B$     |
| 2025-05-09 | 0.03  | 0.12 B$     |
| 2024-11-07 | 0.03  | 0.08 B$     |
| 2025-11-05 | 0.03  | 0.08 B$     |

**Analysis:** EPS shows a significant spike in the most recent quarter (2025-11-05). Revenue is increasing steadily, but the EPS history has fluctuation.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|----------------|
| 2025-09-30   | $0.16B   | 82.63%         |
| 2025-06-30   | $0.14B   | 86.58%         |
| 2025-03-31   | $0.12B   | 87.14%         |
| 2024-12-31   | $0.11B   | 85.77%         |
| 2024-09-30   | $0.08B   | 88.86%         |

**Capital and Profitability:**

| Quarter      | Equity   | ROE      |
|--------------|----------|----------|
| 2025-09-30   | $0.61B   | 64.37%   |
| 2025-06-30   | $0.28B   | 10.20%   |
| 2025-03-31   | $0.24B   | 2.13%    |
| 2024-12-31   | $0.22B   | 10.49%   |
| 2024-09-30   | $0.19B   | 2.02%    |

**Analysis:** Revenue is trending upwards. Profit margins are consistently high. Equity has increased significantly, particularly in the most recent quarter. ROE shows a huge spike in the most recent quarter.

**7) Comprehensive Analysis**

*   **Underperformance:** TGTX has underperformed the S&P 500, with a divergence of -15.1%.
*   **Volatility:** The stock exhibits high volatility, as reflected in its fluctuating CAGR, high MDD, and variable Alpha.
*   **Mixed Signals:** Recent news and financial data present conflicting signals. Strong recent revenue and equity growth with high profitability is countered by news of earnings caveats and a negative expected return.
*   **Short-Term Positive, Long-Term Concern:** Short-term indicators (RSI, PPO, recent divergence change) suggest potential upward movement, but the extremely negative expected return is a major red flag.
*   **Analyst Uncertainty:** The wide range in analyst target prices reflects considerable uncertainty about the stock's future performance.
*   **Overall Assessment:** While the high MRI suggests the investment is recommended, the negative long-term expected return warrants considerable caution. Recent financial performance is positive, but the mixed news and analyst uncertainty indicate a risky investment with potential for both significant gains and losses. Further due diligence is required to understand the factors driving the negative expected return and the impact of competition on future earnings.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.